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Every year, ten millions of people around the world suffer 
from traumatic brain injury (TBI), leading to their disability 
and death. The TBI is a major social, economic, and health 
problem.[1] The World Health Organization has estimated 
that by 2020, TBI will become a common cause of death 
in comparison with other major important diseases.[2] 
Furthermore, TBI often occurs in young people (aged between 
15 and 45 years) and 75% of the victims are men.[3]
At present, there is a group of treatments with more than 
30 years of clinical work, yet they have become flawed. 
Therefore, there is an urgent need to find new neuroprotective 
factors that reduce the complications of TBI.[4]
Investigating the performance of angiotensin 2 (Ang II) and 
angiotensin receptor type 1 (AT1R) and AT2R in the brain 
and after the stroke has shown that AT1R is vastly expressed 
in mature people and causes many of Ang II activities, such 
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as inflammation and vasoconstriction. A2TR expression is 
less in mature individuals, yet it increases due to diseases, 
and its impacts are against AT1R. In other words, it has 
anti-inflammatory, vasodilator, antioxidant, antiapoptotic, 
angiogenesis, and neurogenesis impacts.[5] The balance 
between the two receptors can determine the usefulness of 
Ang II. The consumption of AT1R blockers or the stimulation 
of AT2R causes this balance.[5] It is reported that angiotensin 
receptor blockers (ARBs) can account for such an effect against 
cerebral ischemia.[6]
The decreased expression of transcription factors involved 
in apoptosis[7] and the decreased oxidative stress[8] have been 
reported following estrogen administration after TBI similar 
to AT1R blockers. Reduced brain edema[9] and permeability 
of the blood–brain barrier (BBB)[10] and improved neurologic 
outcomes[11] by estrogen have also been found in our previous 
studies. Other studies have also confirmed reduced cell death 
and increased nerve regeneration and neurotrophic support by 
estrogen following TBI.[12]
On the other hand, considerable evidence suggests that 
estrogen can interfere with renin-angiotensin system (RAS), 
which includes reducing the production of angiotensinogen[13] 
and decreasing angiotensin-converting enzyme (ACE).[13] It 
has been reported that estrogen alpha receptor leads to the 
activation of neuroprotective genes and reduction in the brain 
Ang II.[14] A research shows that estrogen reduces AT1R in 
the brain.[15]
Objectives
Few studies have been done on efficiency and anti-inflammatory 
mechanisms of ARBs alone or in combination with estrogen 
in TBI damages. Therefore, in the present study, we assumed 
that changes in the elements of RAS and activation of AT1R 
after TBI may play a role in damage caused by TBI as well as 
anti-inflammatory effects of estrogen. Therefore, this study was 
designed to assess the effect of candesartan doses ineffective 
on blood pressure as well as the combined effect of estrogen 
and candesartan on brain edema, permeability of the BBB, and 
neurological outcome following TBI in ovariectomized animals.
MatErials and MEthods
Animals
This study was performed according to license 280/93 K issued 
by the Ethics Committee of Kerman University of Medical 
Sciences. In this study, female rats (200–250 g) were housed 
at 20°C–22°C temperature and 12-h light/dark in the animal 
house of Faculty of Medical Sciences.
Drugs
The sesame oil and 17-beta-estradiol were obtained from 
Aburaihan Pharmaceutical Company (Tehran, Iran). 
Candesartan was purchased from the LKT Company in 
America.
Ovariectomy surgery
To eliminate the effect of estrous cycle and ovarian 
steroids, the animals were ovariectomized 2 weeks before 
TBI.[16] A combination of ketamine and xylosin was used 
intraperitoneally. Then, the lower abdominal area was shaved, 
and a small vertical incision was made in the skin of this area. 
The tissues and muscles were opened, and fat and intestines 
were pushed up so that the fallopian tubes could be observed. 
In each ovary, the fallopian tube was tied using a 0.4-mm 
catgut cord in the paroxysmal area, and it was disconnected 
from the distal area.
Finally, after injecting 2 mL of isotonic saline, the muscles and 
skin were stitched and the stitches were disinfected with iodine. 
The animals were under care until the end of the anesthesia.
Experiment protocols
The rats were divided into two groups. One group was 
sham-ovariectomy (OVX, animals whose ovaries were falsely 
removed, n = 7) and another group was OVX (the ovaries 
of these animals were removed 2 weeks before the TBI). 
Then, OVX rats were divided into 10 groups. One group 
experienced false TBI (sham), and the other nine groups had 
real TBI. These groups include (1) TBI, (2) oil (OVX rats that 
received estrogen vehicle [sesame oil] equal to the amount 
of the consumed estrogen, intraperitoneally 30 min after the 
TBI),[17] (3) E2 (OVX rats that received 1 mg/kg of estrogen 
intraperitoneally 30 min after the TBI),[17] (4) Vehicle (Veh, 
similar to oil group with the only difference that they received 
candesartan vehicle (sodium carbonate 0.1 N),[18] (5) LC (OVX 
rats that received 0.1 mg/kg of candesartan intraperitoneally 
30 min after the TBI),[19] (6) HC (the same as LC only with the 
difference that they received 0.3 mg/kg of candesartan),[18] (7) 
oil + Veh (similar Veh only with the difference that they 
received estrogen vehicle + candesartan vehicle [sesame 
oil] + sodium carbonate 0.1 N), (8) E2 + LC (OVX rats that 
received 1 mg/kg of estrogen and 0.1 mg/kg of candesartan 
intraperitoneally 30 min after the TBI), (9) E2 + HC (similar 
to E2 + LC group with the difference that they received 1 mg/
kg of estrogen and 0.3 mg/kg of candesartan).
Induction of diffuse traumatic brain injury
TBI was diffused and created using the Marmarou’s method. 
After putting a metal disc (made of steel with a thickness 
of 3 mm and a diameter of 10 mm) on the skull of the 
animal (between Bregma and Lambda) using polyacrylamide 
glue, the anesthetized animal was put under the TBI 
device (developed in the Kerman Physiology Group). Two 
hundred and fifty grams weight was released from 2 m distance 
through a pipe and landed on the metal disc. After the injury, 
if necessary, the aspiration of the animals was immediately 
brought back by connecting them to the respiratory pumps.[20]
Determination of brain edema
Twenty-four hours after TBI, the brain of anesthetized animal 
was taken out, and after weighing (wet weight), it was kept 
for 72 h in an autoclave at a temperature of 60°C–70°C, and 
then, we weighed it again (dry weight).
Brain water content (BWC, an index of brain edema) was 
calculated using the following formula:[17,21]
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BWC (%) =  ([weight of dry tissue – wet tissue weight]/wet 
tissue weight)× 100
Determining blood–brain barrier disruption
By measuring the extravascular Evans blue content using 
a spectrophotometry, the permeability of the BBB was 
determined. Four hours after the trauma, 20 mg/kg of Evans 
blue color was injected via the jugular vein. One hour after 
the injection (5 h after the trauma), to exit the blue color from 
blood, 200–300 mL of heparin isotonic saline solution was 
diffused into the left ventricle after opening the chest and 
cutting the jugular vein of the two sides. Then, the brain was 
quickly taken out of skull and weighted. After homogenization, 
it was put in 20 mL of solution (14 mL acetone + 6 mL sodium 
sulfate). After 24 h of shaking, 1 mL of the solution was mixed 
with trichloroacetic acid, and after 2–3 min exposure to cold 
temperature, it was centrifuged at 2000 g for 10 min.[17]
Finally, the optical density of 1 mL of supernatant was 
estimated using a spectrophotometer at 620-nm wavelength.
The color (µg/g of tissue) was calculated using the following 
formula:
Evans blue = 13.24 × 20 × optical density/weight tissue.
Investigating neurological outcome
According to the veterinary coma scale (VCS), the 
neurological consequences were measured in the form of 
neurological scores.[3-15] There are three type of scores: motor 
performance (score range: 1–8), eye performance (score 
range: 1–4), and respiratory performance (score range: 1–3),[22] 
which were estimated 1 h before the TBI, immediately after 
TBI, and 1, 4, and 24 h after the TBI. Based on the VCS 
index, the higher scores have a better representation of better 
neurologic outcomes, whereas the lower scores have worse 
representation of neurological outcomes.
Statistical analysis
The results were estimated based on mean ± standard error 
of the mean. To check for normal distribution of the data, 
the Shapiro–Wilk test was used. The data were not normally 
distributed; nonparametric Kruskal–Wallis and Friedman 
tests were used for analysis. P < 0.05 was considered as the 
significance level.
rEsults
Table 1 shows the BWC changes in different groups. The 
BWC in the TBI (78.83 ± 0.12) and oil groups (78.69 ± 0.13) 
was higher than that of sham + OVX (77.87 ± 0.11) 
group (P < 0.001). However, there was no significant 
difference in the BWC between the TBI and oil groups. The 
BWC in the E2 group (78.04 ± 0.14) was lower than that 
of the oil group (P < 0.01). Furthermore, Table 2 shows the 
effect of different doses of candesartan and combination of 
estrogen and candesartan on BWC. The BWC in the HC 
group (78.24 ± 0.15) was significantly reduced compared to 
the Veh group (78.83 ± 0.18) (P < 0.05). The BWC in LC 
and HC groups was not significant; it decreased significantly 
in E2 + LC and E2 + HC groups compared to the oil + Veh 
group (P < 0.01). The BWC was not different among E2 + LC, 
E2 + HC, and E2 groups [Figure 1a]. Figure 1b shows that 
BWC in the E2 + LC group significantly reduced compared to 
the LC group (P < 0.05). However, no significant difference in 
the BWC was observed between the HC and E2 + HC groups.
Figure 2 shows the changes in the content of Evans blue in 
different groups. This index was high in the TBI (38.3 ± 1.33) 
and oil (27.14 ± 0.78) groups compared to the sham + OVX 
group (7.77 ± 1.17) (P < 0.001), and it was not different 
between the TBI and oil groups [Figure 2a]. Figure 2b shows 
a significant reduction of the Evans blue content in the 
E2 group (12.87 ± 0.93) compared to the oil group (P < 0.001). 
The Evans blue content was less in the HC group (14.04 ± 1.5) 
compared to the LC (25.45 ± 1.08) and Veh (30.38 ± 1.09) 
groups (P < 0.001). This indicator was decreased in the LC group 
compared to the Veh group (P < 0.01) [Figure 2c]. Figure 2d 




Data are presented as mean±SEM (n=7 in each group). aVersus sham-OVX and sham + OVX (P<0.001), bVersus Sham-OVX and Sham + OVX 
(P<0.001), cVersus Oil (P<0.01) and TBI (P<0.001). TBI: Traumatic brain injury, Oil: Vehicle of estrogen, E2: Estrogen, SEM: Standard error of the mean, 
OVX: Ovariectomized
Table 2: Changes in the brain water content in the group treated with candesartan and compound groups (24 h after 
traumatic brain injury)
Group
E2 + HCE2 + LCOil + VehHCLCVeh
0.18b±78.150.18b±78.3078.76±0.140.15a±78.240.2±78.590.13±78.83Brain water content
Data are presented as mean±SEM (n=7 in each group). aVersus Veh (P<0.01), bVersus Oil + Veh (P<0.01). Veh: Vehicle of candesartan, LC: Low dose of 
candesartan, HC: High dose of candesartan, Oil + Veh: Vehicle of estrogen + vehicle of candesartan, E2 + LC: Estrogen+low dose of candesartan, E2 + 
HC: Estrogen + high dose of candesartan, SEM: Standard error of the mean
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shows that the Evans blue content significantly decreased in 
the E2 + LC (14.39 ± 1.03) and E2 + HC (13.82 ± 0.59) groups 
compared to the oil + Veh group, and it was not different among 
E2, E2 + LC, and E2 + HC groups. Furthermore, this indicator 
was significantly lower in the E2 + LC group compared to the 
LC group (P < 0.001) [Figure 2e].
Figure 1: (a) The brain water content (%) in different groups treated with estrogen and combination of estrogen and candesartan (n = 7 in each 
group). The results are based on mean ± standard error of the mean. *: P <0.05 versus LC (b). E2: Estrogen, E2 + LC: Estrogen + low dose of 
candesartan, E2 + HC: Estrogen + high dose of candesartan, LC: Low dose of candesartan, HC: high dose of candesartan
a b
Figure 2: Comparison of the Evans blue color (µg/g tissue) in treated and nontreated groups (n = 7 in each group). The results are based on 
mean ± standard error of the mean. ***P < 0.001 versus Sham-OVX and Sham + OVX (a). †††P < 0.001 versus traumatic brain injury. ###P < 0.001 
versus oil (b). †††P < 0.001 versus traumatic brain injury. ##P < 0.01 versus Veh. ###P < 0.001 versus Veh (c). ###P < 0.001 versus oil + Veh (d). 
***P < 0.001 versus LC (e). TBI: Traumatic brain injury, oil: Estrogen vehicle, E2: Estrogen, LC: Low dose of candesartan, HC: High dose of 
candesartan, Veh: Candesartan vehicle, E2 + LC: Estrogen + low dose of candesartan, E2 + HC: Estrogen + high dose of candesartan, Oil + Veh: 
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Neurological outcomes in the different groups and at different 
times of the study in terms of the neurological score are shown in 
Figure 3. Figure 3a shows that there was no significant difference 
in the VCS between the TBI and oil groups in any hour of the study. 
Immediately after the injury, this index was significantly less in the 
TBI (3.33 ± 0.21, P < 0.001) and oil groups (4 ± 0.36, P < 0.001) 
compared to the sham-OVX and sham + OVX (15 ± 0.0) 
groups. The indicator was significantly decreased in the oil and 
TBI groups compared to the sham + OVX group, 1, 4, and 24 
h after TBI (P < 0.001). Figure 3b shows a significant increase 
in neurological scores of the E2 group (12.83 ± 0.16 and 
14.33 ± 0.21) compared to the oil group, 4 and 24 h after TBI, 
respectively (P < 0.01). This index in the E2 group was lower 
compared to that in the TBI, 1, 4 and 24 h after TBI (P < 0.01). 
Figure 3c shows that there was no significant difference in the 
VCS between the LC and Veh groups in all hours. In addition, 
the neurological score had a significant decrease in the HC group 
compared to the Veh group, 4 and 24 h after TBI (P < 0.01).
The index was decreased in the E2 + LC group (9.66 ± 0.3) 
compared to the oil + Veh group, 1 h after TBI (P < 0.05). 
Furthermore, the neurological score was significantly high in 
the E2 + LC and E2 + HC groups compared to the oil + Veh 
group, 4 (P < 0.05) and 24 h (P < 0.01) after TBI. There was 
no significant difference in the VCS among the E2 + LC, 
E2 + HC, and E2 groups in any time after TBI [Figure 3d].
discussion
The results of this study showed the reduction of cerebral 
edema, prevention of BBB destruction, and improvement 
of neurologic outcomes by estrogen and 0.3 mg/kg dose 
of candesartan. Furthermore, although 0.1 mg/kg dose of 
candesartan had no neuroprotective effect, its effects were 
similar to the consumption of a high dose of candesartan when 
combined with estrogen. The BWC and Evans blue content 
increased following TBI 1.23% and 270%, respectively, 
compared to the sham groups; similar changes were also caused 
by oil. The amount of the brain edema content was decreased 
following estrogen administration by 0.83%. Estrogen also 
decreased the Evans blue content (52.58%) compared to the 
oil group.
Figure 3: Changes in treated and non-treated groups at different hours (n = 7 in each group). The results are based on mean ± standard error 
of the mean. ***P < 0.001 in the traumatic brain injury and oil compared to Sham-OVX and Sham + OVX and for all hours after traumatic brain 
injury for all hours after traumatic brain injury (a). ††P < 0.01 for E2 compared to traumatic brain injury, 1, 4, and 24 h after traumatic brain injury. 
##P < 0.01 for E2 compared to oil at 4 and 24 h after traumatic brain injury (b). †P < 0.05 for HC compared to traumatic brain injury in the 1st h 
after traumatic brain injury. ††P < 0.01 for HC compared to traumatic brain injury 4 and 24 h after traumatic brain injury. ##P < 0.01 for HC 
compared to Veh 4 and 24 h after traumatic brain injury (c). #P < 0.05 for E2 + HC in comparison with oil + Veh 1 h of traumatic brain injury. 
#P < 0.05 for E2 + LC in comparison oil + Veh 4 h after traumatic brain injury. ##P < 0.01 for E2 + HC and E2 + LC compared to oil + Veh 
24 h after traumatic brain injury (d). TBI: Traumatic brain injury, Oil: Estrogen vehicle, E2: Estrogen, LC: Low dose of candesartan, HC: High dose 
of candesartan, Veh: Candesartan vehicle, E2 + LC: Estrogen + low dose of candesartan, E2 + HC: Estrogen + high dose of candesartan, 
oil + Veh: Estrogen vehicle + candesartan vehicle
a b
c d
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The loss of BBB integrity could be due to initial damage,[23] 
upregulation of the aquaporins (AQPs),[24] metalloproteinase-9 
(MMP-9),[25] inflammation, and free radicals produced[26] 
after TBI as mechanisms involved in the development of 
cerebral edema. By stabilizing the BBB,[10] reducing AQP4,[27] 
decreasing oxidative stress,[8] reducing cytokines, driving 
inflammation, increasing anti-inflammatory cytokines,[28] 
maintaining cerebral blood flow,[29] inhibiting MMP9,[30] 
estrogen may maintain its antiapoptotic[12] and protective 
effect on keeping the integrity of BBB in turn brain edema 
reduction.[31]
Estrogen has been widely investigated in experimental 
studies of ischemia and hemorrhage brain injury. Almost 
without exception, these studies found that estrogen reduces 
tissue damage and improves performance following injury. 
The results of this study are in line with the results of 
our previous laboratory studies.[9,10,16] Furthermore, other 
studies have reported neuroprotective effects of estrogen on 
reducing cerebral edema, protecting the BBB, and improving 
neurological outcomes. In a study conducted by O’Connor 
et al., it was observed that administration of a single dose of 
estradiol to female rats ½ h after injury caused a significant 
decrease in BWC 24 h after injury in comparison with the 
control group.[17] The results of Naderi et al.’s study also 
showed that estrogen activates neuroprotection against brain 
edema and destruction of BBB through the both receivers.[10]
In spite of much evidence that introduces estrogen as a 
neuroprotective agent, some studies never observed any negative 
or positive impact derived from estrogen consumption. The 
results of the present study could be due to a consumed estrogen 
dose,[32,33] type of TBI, and severity of created TBI.[34] In another 
section of this study, in which the effect of different doses of 
candesartan was investigated, the findings show that only high 
doses of candesartan could decrease BWC for 75% and reduce 
neurological score in different hours after TBI. Although the 
inhibitory effect of candesartan on the Evans blue content was 
applied by both doses, the effects of a high dose were much more 
than a low dose (53.79% compared to 16.23%).
This may indicate the dose-dependent effect of candesartan on 
brain edema and neurological outcome. Furthermore, unlike 
other studies, in this research, 0.1 mg/kg dose of candesartan 
might affect the Evans blue content because of blocking AT1R 
in vascular endothelial brain and the resulting effects on the 
BBB. On the other hand, it seems to have an impact on brain 
edema and neurological outcomes, yet there is a need for more 
concentration. Since it has been reported that there is an inverse 
relationship between brain edema and neurological outcome,[35] 
no effect on neurological outcomes in low concentrations may 
be due to lack of concentration impact on cerebral edema.
ARBs are known for their multiple functions in the brain 
such as reducing inflammation, providing protection against 
stroke, and having direct neuroprotective effect. Candesartan 
is reported to cause reduction of brain injury,[36] increase in 
coronary microcirculation,[37] and the expression of endothelial 
NOS in the brain vessels,[6] reduction of inflammation[38] 
and oxidative stress,[39] prevention of endothelial function 
defection,[6] reduction of TGF1β,[36] activation of peroxisome 
proliferator-activated receptor-gamma,[36] normalization 
of cerebral vascular self-regulation, and inhibition of 
inflammatory signals that reach to brain through the vagus.[40]
Since the AT1R expression in the cerebral cortex is little, it is 
likely that the candesartan neuroprotection has a more general 
effect in reduction of inflammation and oxidative stress through 
its function on other types of cells such as brain vessels.[41] In 
addition, it has been reported that treatment with candesartan 
reduces microglial activity in the injured cortex after TBI,[36] 
and this may count for the beneficial therapeutic effect of 
candesartan. Furthermore, a research conducted by Brdon et al. 
showed improved neurological outcome and reduced infarct 
size in systemic candesartan administration after ischemic 
damage.[42] Panahpour et al. showed that candesartan reduces 
the size of injury and cerebral edema, and it improved the 
outcome of ischemic injury in animal tests.[18]
As it has been stated, several functions in the brain are 
modulated by estrogen, and estrogen probably interferes with 
the AT1R signaling pathway. In another part of this study, the 
effect of different doses of estrogen combined with candesartan 
on various indices was investigated. Given the results, it was 
found that when estrogen is taken with low concentrations of 
candesartan, the effects on the Evans blue will be similar to 
the effects on BWC. In other words, there was no difference 
between estrogen and estrogen and candesartan regarding the 
content of brain water. This was also similar for the Evans blue 
content. In other words, although a low dose reduced the Evans 
blue content, when it was used with estrogen, the maximum 
inhibitory effect was similar to when estrogen was applied 
individually. As a matter of fact, this was true for both the 
groups. On the one hand, the combined effect was not greater 
than the effect of estrogen alone, and on the other hand, the 
impact of using a combination of estrogen and candesartan 
was similar to the effect of estrogen or candesartan alone. The 
impact of consuming a combination of these drugs is not greater 
than the effect of a single dose because maximum efficacy of 
these two drugs cannot go any further or they exerted their 
neuroprotective effects through a common signaling.
Although few studies have examined the effects of estrogen 
in the RAS, the results indicate modulation of RAR activities 
and thus reduction of the harmful effects caused by estrogen, 
insensitivity of AT1R, and increase of protection by AT1R 
blockers.
Possible mechanisms for strengthening candesartan effects by 
estrogen include weakening of AT1R response by estrogen,[43] 
increasing the expression of AT2R,[14] upregulation of ACE2,[44] 
increasing the MASS receptor by estrogen, increasing 
Ang I–VII, and strengthening its signaling pathway.[45]
The results of the present study showed that administration 
of an individual dose or ineffective dose of candesartan on 
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blood pressure (0.3 mg/kg) following diffuse TBI in the 
female rats led to the decrease in cerebral edema, prevention 
of BBB destruction, and improvement of neurological 
outcome. However, a low dose of candesartan (0.1 mg/kg) 
did not have such a neuroprotective effect, yet taking this 
dose in combination with estrogen resulted in the emergence 
of neuroprotective effects.
Moreover, there was no significant difference between 
the effects of estrogen and a high dose of candesartan. 
A combination of estrogen and a high dose of ARB did not 
increase the effects of any of the two drugs, which can suggest 
that probably each of them had different paths for exerting 
their effects or decreasing effect on brain edema cannot 
be more than this. In addition, this study also showed that 
estrogen and candesartan caused neurological improvement 
probably by reducing cerebral edema. However, since the 
effect of candesartan low dose emerged after the consumption 
of estrogen, it may suggest the interaction between estrogen 
and a low dose of candesartan. In the future, it is necessary to 
do more studies to determine the mechanisms and receptors 
of estrogen involved interaction between estrogen and ATR1.
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